Increased morbidity in overweight and obese liver transplant recipients: A single‐center experience of 1325 patients from the United Kingdom

Abdul R. Hakeem, Andrew J. Cockbain, Syed S. Raza, Stephen G. Pollard, Giles J. Toogood, Magdy A. Attia, Niaz Ahmad, Ernest L. Hidalgo, K. Raj Prasad, Krishna V. Menon – 13 February 2013 – Obesity levels in the United Kingdom have risen over the years. Studies from the United States and elsewhere have reported variable outcomes for obese liver transplant recipients in terms of post–liver transplant morbidity, mortality, and graft survival. This study was designed to analyze the impact of the body mass index (BMI) on outcomes following adult liver transplantation.

Assessment of hepatic steatosis by transplant surgeon and expert pathologist: A prospective, double‐blind evaluation of 201 donor livers

Hasan Yersiz, Coney Lee, Fady M. Kaldas, Johnny C. Hong, Abbas Rana, Gabriel T. Schnickel, Jason A. Wertheim, Ali Zarrinpar, Vatche G. Agopian, Jeffrey Gornbein, Bita V. Naini, Charles R. Lassman, Ronald W. Busuttil, Henrik Petrowsky – 13 February 2013 – An accurate clinical assessment of hepatic steatosis before transplantation is critical for successful outcomes after liver transplantation, especially if a pathologist is not available at the time of procurement.

ASC/caspase‐1/IL‐1β signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury

Naoko Kamo, Bibo Ke, Amir A. Ghaffari, Xiu‐da Shen, Ronald W. Busuttil, Genhong Cheng, Jerzy W. Kupiec‐Weglinski – 13 February 2013 – Apoptosis‐associated speck‐like protein containing a caspase recruitment domain (ASC), an adaptor protein for inflammasome receptors, is essential for inducing caspase‐1 activation and the consequent secretion of interleukin‐1β (IL‐1β), which is associated with local inflammation during liver ischemia/reperfusion injury (IRI). However, little is known about the mechanisms by which the ASC/caspase‐1/IL‐1β axis exerts its function in hepatic IRI.

Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation

Deepak Joshi, Siamak Salehi, Helen Brereton, Matthew Arno, Alberto Quaglia, Nigel Heaton, John O'Grady, Kosh Agarwal, Varuna Aluvihare – 13 February 2013 – Recurrent hepatitis C virus (HCV) infection is associated with accelerated fibrosis rates after liver transplantation (LT) and is the leading cause of graft failure. Furthermore, distinguishing recurrent HCV from acute cellular rejection (ACR) can be problematic, and this can lead to inappropriate treatments and adverse outcomes.

The mTOR pathway in hepatic malignancies

Mamatha Bhat, Nahum Sonenberg, Gregory J. Gores – 13 February 2013 – The mechanistic/mammalian target of rapamycin (mTOR) pathway plays a critical role in cellular metabolism, growth, and proliferation and has been evaluated as a target for therapy in various malignancies. The mTOR pathway is a major tumor‐initiating pathway in hepatocellular carcinoma, with up‐regulation seen in up to 50% of tumors. Metformin, which represses mTOR signaling by activating adenosine monophosphate–activated protein kinase, has been shown to decrease liver carcinogenesis in population studies.

Prospective Evaluation of Single‐Operator Peroral Cholangioscopy in Liver Transplant Recipients Requiring an Evaluation of the Biliary Tract

Domingo Balderramo, Oriol Sendino, Rosa Miquel, Cristina Rodriguez de Miguel, Josep M. Bordas, Graciela Martinez‐Palli, Maria L. Leoz, Antoni Rimola, Miguel Navasa, Josep Llach, Andrés Cardenas – 12 February 2013 – In this descriptive study, we examined the role of single‐operator cholangioscopy (SOC) in the evaluation of biliary complications after liver transplantation (LT). We prospectively included adult recipients of deceased donor LT who were referred for endoscopic retrograde cholangiopancreatography between June 2009 and July 2011.

Liver fatty acid binding protein (L‐Fabp) modulates murine stellate cell activation and diet‐induced nonalcoholic fatty liver disease

Anping Chen, Youcai Tang, Victoria Davis, Fong‐Fu Hsu, Susan M. Kennedy, Haowei Song, John Turk, Elizabeth M. Brunt, Elizabeth P. Newberry, Nicholas O. Davidson – 11 February 2013 – Activation of hepatic stellate cells (HSCs) is crucial to the development of fibrosis in nonalcoholic fatty liver disease. Quiescent HSCs contain lipid droplets (LDs), whose depletion upon activation induces a fibrogenic gene program.

Subscribe to